Clinical Trials Logo

Crohns Disease clinical trials

View clinical trials related to Crohns Disease.

Filter by:

NCT ID: NCT06001450 Recruiting - Pregnancy Clinical Trials

Pregnant Women With and Without Crohns Disease to Explore the Role of Plastics and Toxins in Intestinal Inflammation

PLANET
Start date: August 30, 2023
Phase:
Study type: Observational

The PLANET Study aims to determine the impact of microplastics on intestinal inflammation and gut microbiome in order to understand the role of this pollutant on the risk of developing inflammatory bowel disease (IBD) as well as other diseases. With this information, the researchers hope to characterize better the role of environmental pollutants on IBD and develop novel strategies towards prevention.

NCT ID: NCT05452304 Recruiting - Healthy Subjects Clinical Trials

AZD7798 Safety, Tolerability, and Pharmacokinetics After a Single Ascending and Repeat Dose Administrations to Healthy Subjects, and Patients With Crohn's Disease

Start date: July 12, 2022
Phase: Phase 1
Study type: Interventional

This study will assess the safety, tolerability, immunogenicity, and pharmacokinetics (PK), and explore the pharmacodynamics (PD) following single ascending dose administration and repeat dose administration in healthy subjects and patients with Crohn's disease.

NCT ID: NCT04989907 Active, not recruiting - Clinical trials for Inflammatory Bowel Diseases

A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland

Start date: September 8, 2021
Phase:
Study type: Observational

Vedolizumab is a medicine that helps to reduce sensitivity and pain in the digestive system for participants with UC or CD. In this study, adults with UC or CD will be treated with vedolizumab according to their clinic's standard practice. Participants will receive vedolizumab as either an infusion or an injection just under the skin (subcutaneous). The main aim of the study is to observe real-world treatment patterns in participants treated with vedolizumab. The study sponsor will not be involved in how participants are treated but will provide instructions on how the clinics will record what happens during the study.

NCT ID: NCT04959851 Active, not recruiting - Clinical trials for Inflammatory Bowel Diseases

A Study on How Vedolizumab is Given and the Outcomes for Adults With Inflammatory Bowel Disease (VARIETY-Belgium)

Start date: December 2, 2021
Phase:
Study type: Observational

IBD consists of either ulcerative colitis or Crohn's disease. The main aim of this study is to describe real-world treatment patterns in adults with moderate to severe ulcerative colitis or Crohn's disease when treated with vedolizumab. This will include how vedolizumab is given, which can either be an infusion through a vein (intravenous or IV), or an injection just under the skin (subcutaneous injection, or SC).

NCT ID: NCT04940611 Active, not recruiting - Fistula Clinical Trials

A Study of Surgical Interventions in Fistulizing Conditions

Start date: August 5, 2021
Phase:
Study type: Observational

In this study, participants with complex fistulizing conditions will be treated with surgical interventions according to their clinic's standard practice. The aim of the study is to generate real-world evidence on standard of care for surgical interventions and related outcomes when treating complex fistulizing conditions. The study sponsor will not be involved in how participants are treated but will provide instructions on how the clinics will record what happens during the study.

NCT ID: NCT04890262 Completed - Clinical trials for Inflammatory Bowel Diseases

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real-World Practice

VARIETY-AUT
Start date: August 18, 2021
Phase:
Study type: Observational

Vedolizumab is a medicine that helps to reduce symptoms of IBD and the associated inflammation in the digestive system for participants with ulcerative colitis or Crohn's disease. In this study, participants with ulcerative colitis or Crohn's disease will be treated with vedolizumab according to their clinic's standard practice. Participants will receive vedolizumab as either an infusion or an injection just under the skin (subcutaneous). The main aim of the study is to observe real-world treatment patterns in participants treated with vedolizumab. The study sponsor will not be involved in how participants are treated but will provide instructions on how the clinics will record what happens during the study.

NCT ID: NCT04885920 Completed - Clinical trials for Inflammatory Bowel Diseases

A Study on Administration Choices of Vedolizumab and Outcomes for Adults With Inflammatory Bowel Disease (IBD) (VARIETY - CROATIA AND SLOVENIA)

Start date: February 22, 2022
Phase:
Study type: Observational

Inflammatory bowel disease consists of either ulcerative colitis (UC) or Crohn's disease (CD). The main aim of this study is to describe real-world treatment patterns in adults with moderate to severe ulcerative colitis or Crohn's disease when treated with vedolizumab. This will include the administration choices which can either be an infusion through a vein (intravenous or IV), or an injection just under the skin (subcutaneous injection, or SC). Treatment will be determined by the study doctor according to routine clinical practice.

NCT ID: NCT04397263 Active, not recruiting - Crohns Disease Clinical Trials

A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

Start date: June 10, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety of Guselkumab in participants with Crohn's disease.

NCT ID: NCT04151225 Withdrawn - Crohn's Disease Clinical Trials

Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease

COSMIS
Start date: April 5, 2021
Phase: Phase 2
Study type: Interventional

The study will include participants with moderate to severe Crohn's disease. The aim is to evaluate the safety, tolerability, and efficacy of anti-oncostatin M monoclonal antibody (mAb) GSK2330811. This is a parallel group study with Induction and Maintenance periods. During Induction, the first 100 participants randomised will receive a 450mg GSK2330811 SC loading dose followed by 150mg weekly (Q1W), or placebo for 12 weeks. Additional dose-ranging arms will open after the 100th participant is randomized and in addition to placebo and the highest dose arms will also include a 300mg subcutaneous (SC) loading dose followed by 150mg SC every 2 weeks (Q2W) arm, a 300mg loading dose followed by 150mg SC every 4 weeks (Q4W) arm and a 150mg SC every 8 weeks (Q8W) arm. Participants with a clinical response at Week 12 will continue into a 40-week blinded maintenance period and will receive either 150mg SC Q2W, 150mg SC Q4W, 150mg SC Q8W or placebo. Participants without a clinical response at Week 12 will be offered up to 40 weeks of open label treatment with GSK2330811. Approximately 560 participants will be screened to randomize 280.

NCT ID: NCT03981939 Completed - Clinical trials for Inflammatory Bowel Disease

Perianal Fistula (PAF) Validation and Burden of Illness Study

Start date: July 2, 2019
Phase:
Study type: Observational

The purpose of this study is to gain a better understanding of the disease burden and unmet need of perianal fistulas within Crohn's disease (CD) in Ontario.